Josep Lupón1, Hanna K Gaggin2, Marta de Antonio1, Mar Domingo3, Amparo Galán4, Elisabet Zamora1, Joan Vila5, Judith Peñafiel5, Agustín Urrutia1, Elena Ferrer3, Nuria Vallejo3, James L Januzzi2, Antoni Bayes-Genis6. 1. Cardiology Service and Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain. 2. Cardiology Division, Massachusetts General Hospital, Boston, MA, USA. 3. Cardiology Service and Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. 4. Biochemistry Service, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. 5. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; CIBER, Epidemiology and Public Health, Barcelona, Spain. 6. Cardiology Service and Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain. Electronic address: abayesgenis@gmail.com.
Abstract
BACKGROUND: Limited data exists regarding biomarker use to predict left ventricular (LV) reverse remodeling (R2). Our aim was to examine the value of soluble ST2 (ST2), N-terminal-pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and galectin-3 relative to LV-R2 in systolic heart failure (HF), and to develop a clinical score for LV-R2 prediction. METHODS: R2 was defined as a) LV ejection fraction (LVEF) increase ≥15%, or b) LVEF increase ≥10% plus reduction of LV end-systolic diameter index ≥20% or LV end-systolic volume ≥40%, for 12 months. RESULTS: We studied 304 patients (79.6% men, mean age 66.1 ± 12.3 years) with baseline LVEF <40%. R2 was observed in 104 patients (34.2%). In univariable logistic regression, factors associated with R2 were age (p=0.02), non-ischemic etiology of HF (p<0.001), NYHA functional class (p=0.02), baseline LVEF (p=0.005), absence of left bundle branch block (LBBB; p=0.002), ST2 (p=0.004), NT-proBNP (p=0.005), and hs-cTnT (p<0.001); HF duration achieved borderline significance (p=0.08). In multivariable analysis, ST2 remained the only biomarker associated with LV-R2. We developed the ST2-R2 score for use in clinical practice for predicting R2; variables included were ST2 <48 ng/mL, non-ischemic etiology, absence of LBBB, HF duration <12 months, baseline LVEF <24%, and β-blocker treatment. The score had an area under the curve of 0.79 in the derivation cohort and 0.73 in a separate validation cohort. CONCLUSIONS: The ST2-R2 score, which includes the novel biomarker ST2 and five clinical variables, reasonably predicts LV-R2 in systolic HF patients. ST2 was the only studied biomarker that was independently associated with R2.
BACKGROUND: Limited data exists regarding biomarker use to predict left ventricular (LV) reverse remodeling (R2). Our aim was to examine the value of soluble ST2 (ST2), N-terminal-pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and galectin-3 relative to LV-R2 in systolic heart failure (HF), and to develop a clinical score for LV-R2 prediction. METHODS: R2 was defined as a) LV ejection fraction (LVEF) increase ≥15%, or b) LVEF increase ≥10% plus reduction of LV end-systolic diameter index ≥20% or LV end-systolic volume ≥40%, for 12 months. RESULTS: We studied 304 patients (79.6% men, mean age 66.1 ± 12.3 years) with baseline LVEF <40%. R2 was observed in 104 patients (34.2%). In univariable logistic regression, factors associated with R2 were age (p=0.02), non-ischemic etiology of HF (p<0.001), NYHA functional class (p=0.02), baseline LVEF (p=0.005), absence of left bundle branch block (LBBB; p=0.002), ST2 (p=0.004), NT-proBNP (p=0.005), and hs-cTnT (p<0.001); HF duration achieved borderline significance (p=0.08). In multivariable analysis, ST2 remained the only biomarker associated with LV-R2. We developed the ST2-R2 score for use in clinical practice for predicting R2; variables included were ST2 <48 ng/mL, non-ischemic etiology, absence of LBBB, HF duration <12 months, baseline LVEF <24%, and β-blocker treatment. The score had an area under the curve of 0.79 in the derivation cohort and 0.73 in a separate validation cohort. CONCLUSIONS: The ST2-R2 score, which includes the novel biomarker ST2 and five clinical variables, reasonably predicts LV-R2 in systolic HFpatients. ST2 was the only studied biomarker that was independently associated with R2.
Authors: Jordi Pérez-Rodon; Enrique Galve; Carmen Pérez-Bocanegra; Teresa Soriano-Sánchez; Jesús Recio-Iglesias; Eva Domingo-Baldrich; Mila Alzola-Guevara; Ignacio Ferreira-Gonzalez; Josep Ramon Marsal; Aida Ribera-Solé; Laura Gutierrez García-Moreno; Luz María Cruz-Carlos; Nuria Rivas-Gandara; Ivo Roca-Luque; Jaume Francisco-Pascual; Artur Evangelista-Masip; Àngel Moya-Mitjans; David Garcia-Dorado Journal: Eur Cardiol Date: 2017-12
Authors: Sandra Amorim; João Rodrigues; Manuel Campelo; Brenda Moura; Elisabete Martins; Filipe Macedo; J Silva-Cardoso; M Júlia Maciel Journal: Int J Cardiovasc Imaging Date: 2016-12-24 Impact factor: 2.357
Authors: Ana de la Fuente; Marta Santisteban; Josep Lupón; José Manuel Aramendía; Agnes Díaz; Ana Santaballa; Amparo Hernándiz; Pilar Sepúlveda; Germán Cediel; Begoña López; José María López Picazo; Manuel M Mazo; Gregorio Rábago; Juan José Gavira; Ignacio García-Bolao; Javier Díez; Arantxa González; Antoni Bayés-Genís; Susana Ravassa Journal: Cancers (Basel) Date: 2022-06-14 Impact factor: 6.575
Authors: Jonathan Beaudoin; Jagmeet P Singh; Jackie Szymonifka; Qing Zhou; Robert A Levine; James L Januzzi; Quynh A Truong Journal: Can J Cardiol Date: 2016-06-02 Impact factor: 5.223